The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
Abstract
This is a clinical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) study of a single ascending dose (SAD) and a multiple ascending dose (MAD) of the oral direct factor Xa inhibitor edoxaban in healthy males. The placebo‐controlled, single‐blind, randomized, 2‐part study consists of a SAD arm with 85 subjects (10, 30, 60, 90, 120, 150 mg) and a MAD arm with 36 subjects (90 mg daily, 60 mg twice daily, 120 mg daily). Effects of food and formulation (tablet vs solution) are assessed in a crossover substudy. In the SAD, doses are well tolerated up to 150 mg. Exposure is proportional to dose. PK profiles are consistent across dose with rapid absorption, biphasic elimination, and terminal elimination half‐life of 5.8 to 10.7 hours. In the MAD, mean accumulation after daily dosing is 1.10 to 1.13 and consistent with elimination half‐life of 8.75 to 10.4 hours. Intrasubject variability ranges from 12% to 17% for area under the curve. In general, plasma edoxaban concentrations are linearly correlated with coagulation parameters. Edoxaban is safe and well tolerated with no dose‐dependent increases in adverse events. It is concluded that single and multiple doses of edoxaban are safe and well tolerated up to 150 mg with predictable PK and PD profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
FURUGOHRI, T., ISOBE, K., HONDA, Y., KAMISATO‐MATSUMOTO, C., SUGIYAMA, N., NAGAHARA, T., MORISHIMA, Y., & SHIBANO, T. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03064.x · Cited by 301
Factor Xa or thrombin: is factor Xa a better target?
ANSELL, J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02473.x · Cited by 170
Fuji, T., FUJITA, S., TACHIBANA, S., & Kawai, Y. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04021.x · Cited by 137
Zafar, M. U., Vorchheimer, D. A., Gaztañaga, J., Velez, M., Yadegar, D., Moreno, P., Kunitada, S., García‐Pagán, J. C., Fuster, V., & Badimon, J. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-04-0312 · Cited by 124
Self-citationFood-Effect Bioavailability and Fed Bioequivalence Studies
최선옥, 정성희, 엄소영, 정서정, 김주일, & 정수연 (2004) · Journal of Korean Pharmaceutical Sciences · doi:10.4333/kps.2004.34.3.223 · Cited by 114
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation
Connolly, S. J., Eikelboom, J. W., O'Donnell, M. J., Pogue, J. M., & Yusuf, S. (2007) · Circulation · doi:10.1161/circulationaha.107.695163 · Cited by 86
Vasovagal reaction rates and body weight: findings in high‐ and low‐risk populations
Newman, B. H. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00478.x · Cited by 82
Outpatient management of anticoagulation therapy.
du Breuil, A. L., & Umland, E. M. (2007) · PubMed · Cited by 65
Cited by
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Horlocker, T. T., Wedel, D. J., Rowlingson, J. C., Enneking, F. K., Kopp, S. L., Benzon, H. T., Brown, D. L., Heit, J. A., Mulroy, M. F., Rosenquist, R. W., et al. (2010) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0b013e3181c15c70 · Cited by 1,501
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Metadata
- Authors
- Ogata, K., Mendell‐Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M., & Kunitada, S.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2010-07
- Volume
- 50
- Issue
- 7
- Pages
- 743-753
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2027735039
- Cited by
- 453
- References
- 13
- FWCI
- 19.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. https://app.cochat.ai/papers/10.1177/0091270009351883
- The paper
- Ogata, K., Mendell‐Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M., & Kunitada, S. (2010). Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270009351883
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.